Tesaro (TSRO) Post Wider Q1 Loss

Tesaro (NASDAQ: TSRO) reported Q1 EPS of ($1.43), $0.37 worse than the analyst estimate of ($1.06).

"During the first quarter, we continued to advance and expand our development pipeline and achieved several significant milestones," said Lonnie Moulder, CEO of TESARO. "We recently initiated patient treatment in the Phase 3 BRAVO trial of niraparib in patients with BRCA-positive breast cancer, concluded enrollment in our third and final Phase 3 trial of rolapitant, and expanded our pipeline to include a platform of several exciting immuno-oncology targets. We look forward to the presentation of the full dataset from each of three rolapitant pivotal trials at the upcoming ASCO and MASCC meetings, and we remain on track to submit the rolapitant NDA to the U.S. FDA in mid-2014."

For earnings history and earnings-related data on Tesaro (TSRO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c